Skip to main content

Politicians make promises on their stump — we watch and hold them accountable.

Help keep the record honest →Create an account
Bills/119th Congress · House

H.R. 5919

Introduced

Veterans HOPE Act

Sponsor
RGregory F. Murphy· North Carolina
Introduced
November 4, 2025
Policy area
Armed Forces and National Security
Latest action
Referred to the House Committee on Veterans' Affairs.November 4, 2025
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5919 Introduced in House (IH)]

<DOC>

119th CONGRESS
1st Session
H. R. 5919

To direct the Secretary of Veterans Affairs to conduct a review of 
opioid overdose deaths among veterans, and for other purposes.

_______________________________________________________________________

IN THE HOUSE OF REPRESENTATIVES

November 4, 2025

Mr. Murphy (for himself and Mr. Courtney) introduced the following 
bill; which was referred to the Committee on Veterans' Affairs

_______________________________________________________________________

A BILL

To direct the Secretary of Veterans Affairs to conduct a review of 
opioid overdose deaths among veterans, and for other purposes.

Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Veterans Heroin Overdose Prevention 
Examination Act'' or the ``Veterans HOPE Act''.

SEC. 2. FINDINGS; SENSE OF CONGRESS.

(a) Findings.--Congress finds the following:
(1) New research shows that a dramatic rise in opioid 
overdose deaths among veterans in recent years has happened 
increasingly among veterans dying from heroin and synthetic 
opioids.
(2) Furthermore, patients of the Veterans Health 
Administration of the Department of Veterans Affairs are seven 
times more likely to suffer from an opioid use disorder than 
commercially insured patients.
(3) Using records of the Veterans Health Administration 
linked to National Death Index data, the veterans' rate of 
overdose deaths from all opioids increased by 65 percent from 
2010 to 2016, a rate change that includes adjustments for 
demographic changes in the veteran population over time.
(4) Furthermore, among all opioid overdose decedents, 
prescription opioid receipt within three months before death 
declined from 54 percent in 2010 to 26 percent in 2016, yet 
veteran overdoses resulting in death from heroin, synthetic 
opioids such as fentanyl, and nonprescription opioids still 
occurred.
(5) In fact, between 2010 and 2016, the veteran death rate 
from heroin or from taking multiple opioids almost quintupled 
and the death rate from synthetic opioids such as fentanyl 
increased by more than five-fold.
(6) Trends would suggest that, while the aggregate rise in 
opioid overdose deaths among veterans parallel those seen in 
the general population, the increase occurred mainly because of 
a rise in deaths from nonprescribed sources such as heroin, 
fentanyl, other powerful synthetic opioids, or multiple opioids 
in concurrent use.
(b) Sense of Congress.--It is the sense of Congress that further 
veterans overdose prevention efforts and research should extend beyond 
patients actively receiving opioid prescriptions.

SEC. 3. REVIEW OF DEATHS OF VETERANS RELATING TO OPIOID USE.

(a) Review.--Not later than 18 months after the date of the 
enactment of this Act, the Secretary of Veterans Affairs shall complete 
a review of the deaths of all covered veterans who died from opioid 
overdoses during the five-year period preceding the date of the 
enactment for this Act.
(b) Matters Included.--The review under subsection (a) shall 
include the following:
(1) The total number of covered veterans who died from 
opioid overdoses during the five-year period preceding the date 
of the enactment of this Act.
(2) A summary of such veterans that includes the age, sex, 
race, and ethnicity of each such veteran.
(3) A comprehensive list of the medications prescribed to, 
and found in the bodies of, such veterans at the time of death, 
specifically listing any medications that carry a black box 
warning, are off-label, or are psychotropic.
(4) A summary of medical diagnoses by physicians of the 
Department of Veterans Affairs that led to any prescribing of 
the medications referred to in paragraph (3).
(5) The number of instances in which such a veteran was 
concurrently on multiple medications prescribed by physicians 
of the Department.
(6) A summary of--
(A) the average period that elapsed between the 
last prescription opioid receipt and the date of the 
death of such a veteran; and
(B) the cause of death for each such veteran.
(7) The percentage of such veterans with combat experience 
or trauma (including military sexual trauma, traumatic brain 
injury, and post-traumatic stress).
(8) Identification of medical facilities of the Department 
with high prescription and drug abuse treatment rates for 
patients being treated at those facilities.
(9) A description of policies of the Department governing 
the prescribing of medications referred to in paragraph (3).
(10) A description of efforts by the Secretary to 
electronically track, collect, and properly dispose of 
prescription opioids that are either unused, past the 
prescription date, or not in the possession of the properly 
prescribed patient.
(11) A description of any patterns apparent to the 
Secretary based on the review.
(12) Recommendations for further action that would improve 
the safety and well-being of veterans and reduce opioid 
overdose rates for veterans, especially concerning research 
regarding such veterans who had not filed for a opioid 
prescription in the three months before death by overdose.
(c) Public Availability.--Not later than 45 days after the 
completion of the review under subsection (a), the Secretary shall--
(1) submit to Congress a report on the results of the 
review;
(2) make such report publicly available; and
(3) provide to the Committees on Veterans' Affairs of the 
House of Representatives and the Senate a briefing on such 
review.
(d) Definitions.--In this section:
(1) The term ``black box warning'' means a warning 
displayed within a box in the prescribing information for drugs 
that have special problems, particularly ones that may lead to 
death or serious injury.
(2) The term ``covered veteran'' means any veteran who 
received hospital care or medical services furnished by the 
Department of Veterans Affairs during the five-year period 
preceding the death of the veteran.
<all>

Plain-language analysis

Not yet analyzed.

A plain-language breakdown — including any hidden or off-intent provisions and whether the bill was fast-tracked — is generated separately and reviewed before publishing. It will appear here once ready. Until then, the verbatim text above and the official source are the record.

StumpWatch is live, and the record is still growing. Many promises and positions aren’t tracked yet, and some features are still in beta. Add a sourced promise and help keep the record honest.

Help keep the record honest →